[Eradication and chronic acid suppression. Advances and pseudo-advances].
Guidelines for Helicobacter pylori therapy were proposed at the Maastricht 2/2000 conference. Since then no further major developments have been made. An evidenced based choice of treatment is thereby nearly impossible as large randomized trials have not been performed. Minor progress could be achieved in the areas of second-line and rescue treatment options after failure of the standard therapy. At present proton pump inhibitors are the most powerful drugs for the treatment of gastro-oesophageal reflux disease. No additional progress has been achieved concerning therapy of reflux disease in the last years. Reasonable anxiety about the safety of long-term acid suppression with proton pump inhibitors diminished over years as no significant increase in cancer development could be detected.
Turi
S
S
Medizinische Klinik C, Klinikum der Stadt Ludwigshafen gGmbH. MedCLu@t-online.de
Schilling
D
D
Riemann
J F
JF
D000818:Animals; D000863:Antacids / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000209:etiology; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D010818:Practice Patterns, Physicians' / Q000639:trends; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
D000863:Antacids; D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors